X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Nasal Vaccination Improves COVID-19 Protection In Australia

Content Team by Content Team
21st November 2022
in News, Research & Development

Researchers from Australia’s Centenary Institute and the University of Sydney have created a novel nasal vaccination system that promotes strong lung resistance and tolerance against the SARS-CoV-2 coronavirus.

The newly developed vaccine strategy, which was successfully tested in mice and was published recently in Nature Communications, has the potential to be an effective tool for strengthening defences against COVID-19 infection and reducing ongoing viral dissemination.

The vaccine has been administered by simply blowing through the nose and is composed of the SARS-CoV-2 spike protein and an adjunct called Pam2Cys (a chemical that aids in stimulating a higher immune response within the body). In the lungs and airways of the tested animals, it induced significant levels of specific antibodies and elevated T-cell responses.

In the study on mice, the vaccine entered the respiratory system and remained there, attaching to the tissues of the nasal passage, airways, and lungs. According to testing, the lungs’ T-cell responses had grown and the airways were producing significant amounts of protective antibodies. It’s noteworthy that none of the immunised mice contracted COVID-19.

Dr. Anneliese Ashhurst, the study’s lead author and a research fellow at the Centenary Institute and Faculty of Medicine and Health at the University of Sydney, stated that the current SARS-CoV-2 vaccinations significantly reduce death and severe disease, but prevention against infections is less effective. Breakthrough infections are still happening because COVID-19 can still be transferred by those who have received the vaccination. They require a novel vaccine strategy that limits COVID-19 transmission in order to stop viral spread and stop this virus from evolving. This vaccine differs from the majority of the currently available COVID-19 vaccines in that it allows for the direct production of an immune response in the nose, airways, and lungs- areas of the body that are most likely to be the first site of contact with the virus. This may clarify why the vaccine is successful.

The head of the Centenary Institute’s tuberculosis research programme and senior study author, Professor Emeritus Warwick Britton, suggested that the novel vaccine approach could be crucial in the fight against several diseases. The strategy devised here, according to Britton, may help interrupt the COVID-19 infection cycle and will probably impact future coronavirus vaccine related studies.

He came to the conclusion that modifications of the new nasal vaccination might also be used to treat other bacterial or viral respiratory illnesses such as influenza, avian flu, SARS, and MERS.

Previous Post

Kidney Cancer UK Gains Breakthrough NICE Clinical Funding

Next Post

Leprosy-Causing Bacteria May Be Able To Regenerate Livers

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Leprosy-Causing Bacteria May Be Able To Regenerate Livers

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In